On this page
DYT28 childhood-onset dystonia
This condition presents with sustained or intermittent muscle contractions causing twisting movements and abnormal postures, often starting in the legs before spreading to other body regions. The disorder follows an autosomal dominant inheritance pattern and is caused by pathogenic variants in the KMT2B gene.
Overview
DYT28 childhood-onset dystonia represents a genetically defined form of early-onset dystonia, a category of movement disorders affecting muscle control. The condition typically manifests during childhood, with most individuals developing symptoms between the ages of two and ten years. Research suggests this dystonia subtype follows a progressive course, meaning symptoms generally worsen over time, though the rate and extent of progression varies considerably between affected individuals.
The disorder belongs to a broader group of genetic dystonias that share similar clinical features but arise from different underlying genetic causes. DYT28 specifically refers to dystonia caused by pathogenic variants in the KMT2B gene. Evidence suggests the condition is rare, though precise prevalence figures in the UK population have not been established. Recognition of this specific genetic subtype has improved in recent years as genetic testing has become more widely available through NHS pathways.
Understanding the genetic basis of DYT28 matters clinically because it helps families understand inheritance risks, guides treatment approaches, and enables clinicians to anticipate the natural history of the condition. The identification of KMT2B as the causative gene has also revealed important insights into how gene regulation influences neurological development and function.
Symptoms & clinical features
The characteristic clinical feature of DYT28 is dystonia - involuntary muscle contractions that produce twisting, repetitive movements or abnormal postures. In most affected children, symptoms initially appear in the lower limbs, particularly affecting gait and leg positioning. Parents often notice their child developing an unusual walking pattern, toe-walking, or difficulty with coordination during everyday activities. The dystonia typically begins focally, affecting one body region, before spreading to involve additional muscle groups over months to years.
As the condition progresses, dystonia commonly extends to the trunk and upper limbs, and may affect facial muscles, speech, and swallowing. Some individuals develop cervical dystonia, causing involuntary head turning or tilting. The severity of muscle contractions often fluctuates throughout the day, with many children experiencing worsening symptoms during periods of fatigue, stress, or physical activity. A notable feature in some cases is diurnal variation, where symptoms improve with rest or sleep.
Beyond motor symptoms, many affected individuals experience additional neurological features. Developmental delay or cognitive impairment has been reported in some cases, though intellectual ability varies widely. Speech difficulties may arise both from dystonia affecting the vocal apparatus and from broader language development challenges. Psychiatric features, including anxiety and obsessive behaviours, have been observed in a subset of individuals with KMT2B-related dystonia. The constellation of symptoms and their severity differs markedly between affected individuals, even within the same family.
Video: Genetics 101
Affected organs
The primary impact of DYT28 involves the central nervous system, specifically the brain regions controlling voluntary movement. The basal ganglia - deep brain structures that coordinate motor planning and execution - appear to be particularly affected, though the precise neuropathological changes remain under investigation. Research suggests that altered gene regulation during brain development and ongoing neurological function contributes to the motor control abnormalities characteristic of this condition.
While dystonia itself represents a neurological phenomenon, the sustained muscle contractions can produce secondary effects on the musculoskeletal system. Prolonged abnormal posturing may lead to joint contractures, where muscles and tendons shorten, limiting range of motion. Spinal curvature abnormalities, including scoliosis, develop in some individuals due to asymmetric muscle tone. Chronic muscle overactivity can cause pain and fatigue, affecting quality of life even beyond the visible movement disorder. In cases where bulbar muscles are involved, swallowing difficulties may impact nutritional status and increase aspiration risk.
Risks & severity
The severity spectrum for DYT28 spans from relatively mild, focal dystonia to severe, generalised disease causing significant disability. Most individuals fall somewhere in the middle of this range, experiencing progressive symptoms that interfere with daily activities but permit some degree of independent function. The age at symptom onset appears to influence overall severity, with earlier onset generally associated with more extensive eventual involvement, though exceptions occur.
Long-term outlook varies considerably. Some affected individuals maintain the ability to walk independently into adulthood, particularly if symptom progression plateaus or responds well to treatment interventions. Others require mobility aids or wheelchairs as dystonia becomes more generalised and severe. The progressive nature of the condition means functional abilities often decline during childhood and adolescence, though the rate of progression differs between individuals. Speech and swallowing involvement, when present, carries additional risks including nutritional compromise and aspiration pneumonia. Life expectancy data specific to DYT28 remains limited, though the primary concerns relate to complications of severe dystonia rather than the condition being inherently life-limiting. Cognitive and psychiatric features, when present, add further complexity to the clinical picture and influence overall quality of life and care needs.
Genetic causes
DYT28 childhood-onset dystonia results from pathogenic variants in the KMT2B gene, located on chromosome 19. This gene encodes lysine methyltransferase 2B, a protein belonging to a family of enzymes that modify histones - the protein structures around which DNA wraps inside cells. KMT2B specifically adds methyl groups to histone H3 at lysine position 4, a chemical modification that influences whether nearby genes become activated or remain silent. Through this epigenetic mechanism, KMT2B helps regulate the expression of numerous genes during brain development and throughout life.
The normal KMT2B protein plays a particularly important role in neurons, where it appears to control genes involved in neuronal differentiation, synaptic function, and maintaining cellular identity. Evidence suggests the protein functions as part of larger multi-protein complexes that coordinate chromatin remodelling - the process by which DNA accessibility changes to allow or prevent gene transcription. This regulatory role proves essential for proper brain development and the establishment of neural circuits controlling movement.
Pathogenic variants in KMT2B disrupt the protein's methyltransferase activity or its ability to interact with partner proteins in the regulatory complex. Most disease-causing variants are loss-of-function changes, meaning they reduce or eliminate the protein's normal activity rather than creating an abnormally functioning protein. This haploinsufficiency - having only one working copy of the gene instead of the usual two - appears sufficient to cause disease in the autosomal dominant inheritance pattern characteristic of DYT28. The mechanism by which reduced KMT2B function specifically causes dystonia rather than other neurological phenotypes remains an active area of research, though it likely relates to the particular vulnerability of basal ganglia circuits to disrupted gene regulation during critical developmental windows.
- KMT2B lysine methyltransferase 2BKMT2B encodes a histone methyltransferase enzyme that regulates gene expression, with pathogenic variants linked to childhood-onset dystonia and related neurodevelopmental disorders.
Inheritance pattern
DYT28 follows an autosomal dominant pattern of inheritance, meaning a pathogenic variant in just one copy of the KMT2B gene (out of the two copies everyone carries) is sufficient to cause the condition. Each child of an affected parent has a 50 per cent chance of inheriting the altered gene and therefore developing the disorder. The condition affects males and females equally, as the KMT2B gene sits on chromosome 19, not on the sex chromosomes.
However, a substantial proportion of DYT28 cases arise from de novo variants - new genetic changes that occur for the first time in the affected individual rather than being inherited from a parent. When a case results from a de novo variant, neither parent carries the pathogenic change, and the recurrence risk for future siblings is low, typically 1-2 per cent, due to the theoretical possibility of germline mosaicism. For individuals with DYT28 due to de novo variants, each of their own children would still face the 50 per cent inheritance risk. Genetic testing of parents can clarify whether a variant was inherited or occurred de novo, information that proves valuable for family planning discussions and understanding risks to extended family members.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of DYT28 requires both clinical assessment and genetic confirmation. The process typically begins when a child presents with progressive dystonia, prompting evaluation by a paediatric neurologist. Clinical examination focuses on characterising the movement disorder, assessing its distribution and severity, and identifying any associated neurological features. Brain imaging, usually MRI, helps exclude structural abnormalities or other conditions that might cause secondary dystonia, though imaging typically appears normal in DYT28.
Genetic testing provides definitive diagnosis by identifying a pathogenic variant in KMT2B. This typically involves targeted sequencing of genes associated with childhood-onset dystonia or broader gene panel testing for movement disorders. Testing is usually accessed through NHS clinical genetics services following referral from neurology. The relevant R-code for testing through the NHS Genomic Medicine Service is R59 (Early onset dystonia), which includes KMT2B in its associated gene panel. Interpretation of KMT2B variants requires careful assessment of available evidence, as not all changes in this gene cause disease - variants of uncertain significance sometimes emerge, necessitating additional family studies or functional research to clarify pathogenicity. Genetic counselling should accompany testing to ensure families understand the implications of results for the patient and relatives.
Management & lifestyle
Management of DYT28 focuses on symptom control, maintaining function, and preventing complications, as no curative treatment currently exists. A multidisciplinary approach involving paediatric neurology, physiotherapy, occupational therapy, and speech and language therapy provides comprehensive care tailored to individual needs. Medication trials often represent the first-line approach, with various drugs used to manage dystonia, though response varies between individuals and no single agent proves universally effective.
Deep brain stimulation (DBS) has emerged as an important treatment option for individuals with severe, medication-refractory dystonia. This neurosurgical intervention involves implanting electrodes in specific brain regions - most commonly the globus pallidus interna - to modulate abnormal neural activity. Research suggests DBS can produce meaningful symptom improvement in some individuals with KMT2B-related dystonia, though outcomes vary and careful patient selection matters. The intervention requires ongoing programming adjustments and battery replacements, representing a long-term commitment.
Physiotherapy helps maintain range of motion, prevent contractures, and optimise remaining motor function. Occupational therapy addresses activities of daily living, recommending adaptive equipment and strategies to maximise independence. Speech and language therapy supports communication and swallowing safety when these functions are affected. Orthopaedic monitoring watches for scoliosis or other skeletal complications. Nutritional support, sometimes including feeding tube placement, may become necessary if swallowing difficulties compromise intake. Addressing any cognitive, learning, or psychiatric features requires additional support through educational services and mental health professionals. Regular follow-up within specialist neurology clinics allows monitoring of disease progression and adjustment of treatment approaches over time.
UK care pathway
Access to care for DYT28 in the UK typically begins through GP referral to paediatric neurology services when concerning movement patterns emerge in childhood. Once dystonia is identified clinically, the paediatric neurologist may refer to clinical genetics for diagnostic genetic testing, particularly when family history or clinical features suggest an inherited cause. Genetic testing for dystonia-associated genes, including KMT2B, falls within the NHS Genomic Medicine Service remit, with specific eligibility criteria outlined in the National Genomic Test Directory under relevant R-codes for movement disorders.
Following genetic confirmation of DYT28, ongoing care typically involves coordinated input from multiple specialties. Genetic counselling services provide families with information about inheritance patterns, recurrence risks, and implications for relatives who may wish to pursue predictive or carrier testing. Access to specialist dystonia clinics, where available, offers concentrated expertise in managing this complex condition. The NHS also provides access to specialised services for deep brain stimulation assessment and implantation at designated neuroscience centres for appropriate candidates. Care coordination often involves paediatric neurodisability teams who can link families with therapies, educational support, and community services to address the broader impact of living with a progressive neurological condition.
Frequently asked questions
Will my child's dystonia symptoms continue to worsen throughout their life?
The progression pattern varies between individuals with DYT28. Many experience worsening symptoms during childhood and adolescence, though the rate and extent differ considerably. Some individuals find their symptoms plateau at some point, whilst others continue to experience gradual progression. Your child's neurologist can monitor their specific trajectory and adjust treatment approaches accordingly.
If my child has DYT28 from a new genetic change, what are the chances it could happen again in another pregnancy?
When DYT28 results from a de novo variant (new change not inherited from parents), the recurrence risk for future siblings is low, typically quoted as 1-2 per cent. This small residual risk exists because of the theoretical possibility of germline mosaicism. A clinical geneticist or genetic counsellor can discuss your family's specific situation and testing options.
Are there any medications that work particularly well for KMT2B-related dystonia?
No single medication proves effective for everyone with DYT28, and treatment response varies considerably between individuals. Neurologists typically try various agents including anticholinergics, baclofen, and others used for dystonia management. Some families find certain medications provide meaningful benefit whilst others see limited response, often requiring trials of multiple drugs to identify the most helpful regimen for a particular child.
Should my other children be tested for the KMT2B variant if they don't have any symptoms?
Testing asymptomatic children raises complex considerations that warrant discussion with a genetic counsellor. If the affected child's variant was inherited from a parent, that parent's other children have a 50 per cent chance of carrying it. However, predictive testing of asymptomatic minors is generally only offered when medical management would differ based on results. Your genetics team can explore the specific circumstances and help your family make an informed decision.
Could deep brain stimulation be an option for my child, and when would this be considered?
Deep brain stimulation may be considered for individuals with severe dystonia that significantly impacts function and quality of life despite medication trials. The decision involves careful assessment by a specialist multidisciplinary team, weighing potential benefits against surgical risks and the commitment to ongoing device management. Not everyone proves a suitable candidate, and timing depends on individual circumstances. Your child's neurologist can discuss whether and when DBS assessment might be appropriate.